A Phase 2 Study of Single Agent Depsipeptide (FK228) in Gastric and Esophageal Cancers

Trial Profile

A Phase 2 Study of Single Agent Depsipeptide (FK228) in Gastric and Esophageal Cancers

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 22 Jan 2013 Actual initiation date changed from Dec 2004 to Oct 2004 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top